By Counterforce Health Team in Soliris (eculizumab) —

The Requirements Checklist to Get Soliris (Eculizumab) Covered by Humana in New Jersey

Answer Box: Getting Soliris (Eculizumab) Covered by Humana in New Jersey

Soliris (eculizumab) requires prior authorization from Humana Medicare Advantage plans in New Jersey. The fastest path to approval: (1) Verify active coverage and submit via CenterWell Specialty Pharmacy with complete clinical documentation, (2) Include meningococcal vaccination records and FDA-approved indication diagnosis (PNH, aHUS, gMG, or NMOSD), (3) Use HCPCS code J1299 (effective April 1, 2025) with proper ICD-10 codes. Appeals must be filed within 65 days; New Jersey's IHCAP external review provides additional protection after internal appeals are exhausted.

Table of Contents

  1. Who Should Use This Checklist
  2. Member & Plan Basics
  3. Clinical Criteria Requirements
  4. Coding Requirements
  5. Documentation Packet
  6. Submission Process
  7. Specialty Pharmacy Routing
  8. After Submission
  9. Common Denial Prevention Tips
  10. Appeals Process in New Jersey
  11. Printable Requirements Checklist

Who Should Use This Checklist

This checklist is designed for patients, caregivers, and healthcare providers seeking Humana coverage for Soliris (eculizumab) in New Jersey. Use this guide if you have:

  • A Humana Medicare Advantage plan
  • An FDA-approved indication for Soliris (PNH, aHUS, myasthenia gravis, or NMOSD)
  • Received a denial or need to submit an initial prior authorization request

Expected outcome: Following this checklist increases approval likelihood by ensuring complete documentation and proper submission procedures. Counterforce Health helps patients and providers navigate complex prior authorization requirements by turning denials into targeted, evidence-backed appeals.

Member & Plan Basics

✓ Verify Active Coverage

  • Confirm Humana Medicare Advantage enrollment
  • Check current plan year and formulary status
  • Verify deductible status (Part B covers Soliris at 80% after deductible)
  • Confirm New Jersey residency for state-specific appeal rights

✓ Plan Type Requirements

Humana Medicare Advantage: Soliris requires prior authorization under medical Part B benefit for all FDA-approved indications. Coverage follows Humana Medical Policy MA-108 and CMS guidelines.

Clinical Criteria Requirements

✓ FDA-Approved Indications Only

Soliris is FDA-approved for:

Condition ICD-10 Code Key Requirements
Paroxysmal Nocturnal Hemoglobinuria (PNH) D59.5 Flow cytometry showing CD55/CD59 deficiency; LDH >1.5x upper limit
Atypical HUS (aHUS) D59.31, D59.32, D59.39 Microangiopathic hemolytic anemia; exclude STEC-HUS
Myasthenia Gravis (gMG) G70.00, G70.01 Anti-AChR antibody positive; inadequate response to ≥2 immunosuppressants
NMOSD G36.0 AQP4-IgG positive; core clinical characteristics per 2015 IPND criteria

✓ Safety Requirements (Mandatory)

  • Meningococcal vaccination ≥2 weeks prior to first dose (MenACWY + MenB)
  • Documentation of vaccination dates and types
  • REMS program enrollment confirmation
  • Patient safety counseling documentation

Coding Requirements

✓ HCPCS J-Codes (Critical Update)

Important: Soliris J-codes changed on April 1, 2025:

Effective Period HCPCS Code Dosage per Unit Example: 1200mg Dose
Before 4/1/2025 J1300 10 mg 120 units
On/After 4/1/2025 J1299 2 mg 600 units

✓ Required Modifiers

  • RE: Full compliance with FDA REMS
  • JZ: Zero drug discarded (when applicable)
  • TB: 340B drug pricing program (informational)

✓ NDC Format

Use 11-digit HIPAA format: N42568200010 for 300 mg/30 mL vial. Medicare requires NDC on all medical claims with HCPCS codes.

Documentation Packet

✓ Provider Letter Requirements

  • Prescriber letterhead and NPI
  • Patient demographics and insurance information
  • Primary diagnosis with ICD-10 code
  • Clinical rationale for Soliris specifically
  • Treatment history showing inadequate response to alternatives
  • Dosing and monitoring plan
  • Prescriber signature and date

✓ Laboratory Documentation

For PNH:

  • Flow cytometry results showing CD55/CD59-deficient clones >10%
  • LDH >1.5x upper limit of normal
  • Hemolysis markers
  • Transfusion history

For aHUS:

  • LDH elevated
  • Platelets <150,000/μL
  • Evidence of microangiopathic hemolytic anemia
  • Absence of Shiga toxin (to exclude STEC-HUS)

For Myasthenia Gravis:

  • Positive AChR antibody with titer and date
  • MG-ADL or QMG scores
  • Documentation of inadequate response to ≥2 immunosuppressants

For NMOSD:

  • AQP4-IgG positive results
  • MRI findings consistent with NMOSD
  • Attack history documentation

✓ Supporting Documents

  • FDA prescribing information
  • Relevant clinical guidelines or literature
  • Prior authorization forms (use Humana's Soliris-specific form)
  • Medical records supporting diagnosis and treatment history

Submission Process

✓ Correct Form and Portal

  • Use current Humana prior authorization form
  • Submit via Humana provider portal (fastest - typically 1-day decision)
  • Alternative: Fax to CenterWell Specialty Pharmacy at 1-877-405-7940
  • Include all required fields to avoid automatic rejection

✓ Common Rejection Points

  • Verify patient ID and member number accuracy
  • Confirm ICD-10 code matches primary diagnosis
  • Ensure J-code is appropriate for date of service
  • Check that NDC matches vial size being billed
  • Calculate units correctly (mg ÷ mg per unit)

Specialty Pharmacy Routing

✓ CenterWell Specialty Pharmacy (Required)

Humana requires Soliris to be dispensed exclusively through CenterWell Specialty Pharmacy.

  • Patient enrollment: Call CenterWell at 1-800-486-2668
  • Prescription submission: Fax to 1-877-405-7940 or e-prescribe (NCPDP ID: 3677955)
  • Verify network participation to avoid out-of-network costs
Note: CVS Specialty and Accredo are not Humana's preferred vendors for Soliris. Using non-preferred pharmacies risks denial or high out-of-pocket costs.

After Submission

✓ Track Your Request

  • Record confirmation number from submission
  • Set calendar reminder for follow-up (standard decisions: 30 days for pre-service, 60 days post-service)
  • Monitor for requests for additional information
  • Keep copies of all submitted documents

✓ Status Check Schedule

  • Week 1: Confirm receipt and completeness
  • Week 2-3: Check for any requests for additional information
  • Week 4: Follow up if no decision received for standard requests

Common Denial Prevention Tips

Five Critical Pitfalls to Avoid

  1. Incomplete Vaccination Documentation
    • Fix: Include specific dates and vaccine types for meningococcal vaccination
    • Supporting language: "Patient received MenACWY on [date] and MenB on [date], meeting FDA requirements"
  2. Missing Diagnostic Confirmation
    • Fix: Include flow cytometry for PNH, AQP4-IgG for NMOSD, or AChR antibodies for gMG
    • Supporting language: Use terms like "complement-mediated," "refractory to," and specific lab values
  3. Wrong J-Code for Date of Service
    • Fix: Use J1300 for services before April 1, 2025, and J1299 for services on/after April 1, 2025
  4. Inadequate Prior Therapy Documentation
    • Fix: Document specific therapies tried, duration, and reason for discontinuation
    • Supporting language: "Inadequate response to [therapy] after [duration]" or "Intolerance due to [specific adverse effect]"
  5. Non-Preferred Pharmacy Submission
    • Fix: Route all prescriptions through CenterWell Specialty Pharmacy
    • Verify: Confirm patient enrollment and prescription receipt

Appeals Process in New Jersey

✓ Humana Internal Appeals

Timeline: 65 days from denial date to file appeal Decision timeframe:

  • Pre-service: 30 calendar days
  • Post-service: 60 calendar days
  • Part D: 7 calendar days

How to file:

  • Online through Humana's portal
  • Mail or fax using Humana's Appeal, Complaint or Grievance Form
  • Phone or through your provider

✓ New Jersey External Review (IHCAP)

After completing Humana's internal appeal process, New Jersey residents have additional protection through the Independent Health Care Appeals Program (IHCAP).

Key Details:

  • Timeline: 4 months (180 days) from final internal denial
  • Process: Submit directly to Maximus Federal Services (contracted by NJ DOBI)
  • Cost: Free to patients (insurers pay all costs)
  • Decision: Binding on insurers if overturned

Contact Information:

  • IHCAP Hotline: 1-888-393-1062
  • NJ DOBI Consumer Hotline: 1-800-446-7467
From our advocates: "We've seen many Soliris denials overturned at the external review level in New Jersey when patients include detailed clinical documentation and cite the FDA prescribing information. The key is demonstrating that the denial contradicts standard medical practice for the specific indication."

✓ Expedited Appeals

Available when waiting for standard decision could seriously harm health. Contact Humana immediately if urgent care is needed.

Printable Requirements Checklist

Before Submission:

  • Active Humana Medicare Advantage coverage verified
  • FDA-approved indication confirmed with proper ICD-10 code
  • Meningococcal vaccination completed ≥2 weeks prior
  • REMS enrollment documentation ready
  • Laboratory results supporting diagnosis included
  • Prior therapy failures documented
  • Correct J-code selected (J1299 for dates on/after 4/1/2025)
  • NDC format correct (N42568200010 for 300mg vial)
  • Required modifiers included (RE, JZ as applicable)

Submission:

  • CenterWell Specialty Pharmacy enrollment completed
  • Humana-specific prior authorization form used
  • All required fields completed
  • Confirmation number recorded
  • Follow-up calendar reminders set

If Denied:

  • Appeal filed within 65 days
  • Additional clinical evidence included
  • External review option (IHCAP) noted for New Jersey residents

Frequently Asked Questions

How long does Humana prior authorization take for Soliris in New Jersey? Standard decisions take 30 days for pre-service requests and 60 days for post-service. Part D appeals are decided within 7 days. Expedited reviews are available for urgent cases.

What if Soliris is not on Humana's formulary? Soliris requires prior authorization but is typically covered under medical Part B for FDA-approved indications. You can request a formulary exception if needed.

Can I request an expedited appeal in New Jersey? Yes, expedited appeals are available when waiting could seriously harm your health. Contact Humana immediately and provide supporting documentation from your physician.

Does step therapy apply to Soliris with Humana? Current Humana policies don't show explicit step therapy requirements for Soliris, but documentation of prior therapy failures strengthens approval chances.

What happens if my internal appeal is denied? New Jersey residents can file an external review through IHCAP within 180 days of the final internal denial. This review is free and binding on insurers.

Counterforce Health specializes in helping patients and providers navigate complex prior authorization requirements like those for Soliris. Our platform ingests denial letters, plan policies, and clinical notes to create targeted, evidence-backed appeals that align with payer-specific requirements and improve approval rates.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and requirements may change. Always verify current information with Humana and consult with healthcare providers for medical decisions. For additional help with New Jersey insurance issues, contact the NJ Department of Banking and Insurance at 1-800-446-7467.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.